{"id":50172,"date":"2025-12-08T21:23:10","date_gmt":"2025-12-08T13:23:10","guid":{"rendered":"https:\/\/flcube.com\/?p=50172"},"modified":"2025-12-08T21:23:11","modified_gmt":"2025-12-08T13:23:11","slug":"weixikang-lidocaine-tetracaine-cream-nmpa-clinical-trial-approval","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50172","title":{"rendered":"Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval"},"content":{"rendered":"\n<p><strong>Tibet Weixikang Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/603676:SHA\">SHA: 603676<\/a>) announced that its <strong>lidocaine-tetracaine cream<\/strong> has received approval from the <strong>China National Medical Products Administration (NMPA)<\/strong> to conduct clinical trials for <strong>local anesthesia of intact skin prior to adult dermatological surgeries<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-drug-profile\">Regulatory Milestone &amp; Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Tibet Weixikang Pharmaceutical Co., Ltd. (603676.SH)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Lidocaine-tetracaine cream (generic of Pliaglis)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA clinical trial approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Local anesthesia of intact skin before dermatological surgeries (adults)<\/td><\/tr><tr><td><strong>Reference Listing<\/strong><\/td><td>Included in 31st batch of NMPA&#8217;s reference list for chemical generics<\/td><\/tr><tr><td><strong>Market Exclusivity<\/strong><\/td><td>No domestic product currently available in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-origin-amp-formulation-details\">Origin &amp; Formulation Details<\/h2>\n\n\n\n<p><strong>Original Development:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Originator<\/strong>: Zars Pharma<\/li>\n\n\n\n<li><strong>US FDA Approval<\/strong>: June\u202f29\u202f2006<\/li>\n\n\n\n<li><strong>Brand Name<\/strong>: Pliaglis<\/li>\n\n\n\n<li><strong>Composition<\/strong>: 70\u202fmg lidocaine + 70\u202fmg tetracaine per gram of cream<\/li>\n<\/ul>\n\n\n\n<p><strong>Mechanism of Action:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Dual local anesthetic combining <strong>amide (lidocaine)<\/strong> and <strong>ester (tetracaine)<\/strong> anesthetics<\/li>\n\n\n\n<li>Provides rapid onset and prolonged duration of action for dermatological procedures<\/li>\n\n\n\n<li>Applied as a topical cream on intact skin prior to surgery<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market Segment<\/th><th>China Market Size<\/th><th>Current Status<\/th><th>Commercial Opportunity<\/th><\/tr><\/thead><tbody><tr><td><strong>Topical Anesthetics<\/strong><\/td><td>\u00a52.1\u202fbillion (\u2248\u202fUS$290\u202fmillion)<\/td><td>Dominated by single-agent lidocaine products<\/td><td>High unmet need for dual-agent, long-acting formulation<\/td><\/tr><tr><td><strong>Dermatological Surgery<\/strong><\/td><td>&gt;5 million procedures annually<\/td><td>Limited advanced topical anesthesia options<\/td><td>Premium pricing potential for Pliaglis generic<\/td><\/tr><tr><td><strong>Generic Competition<\/strong><\/td><td>None domestically<\/td><td>First generic applicant advantage<\/td><td>3-5 year market exclusivity window if approved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Advantages:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-to-Market<\/strong>: Potential first domestic generic of Pliaglis<\/li>\n\n\n\n<li><strong>Clinical Need<\/strong>: Addresses demand for long-acting topical anesthesia in cosmetic and therapeutic dermatology<\/li>\n\n\n\n<li><strong>Reimbursement Pathway<\/strong>: Dermatological surgery indication may qualify for outpatient procedure coverage<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline-amp-commercial-outlook\">Development Timeline &amp; Commercial Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Activities<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Clinical Trial<\/strong><\/td><td>Bioequivalence vs. Pliaglis, safety in Chinese patients<\/td><td>Q1\u202f2026 \u2013 Q4\u202f2026<\/td><\/tr><tr><td><strong>NDA Submission<\/strong><\/td><td>Package clinical data for NMPA review<\/td><td>H1\u202f2027<\/td><\/tr><tr><td><strong>Potential Approval<\/strong><\/td><td>Market authorization for dermatological anesthesia<\/td><td>2028<\/td><\/tr><tr><td><strong>Commercial Launch<\/strong><\/td><td>Multi-channel distribution to dermatology clinics<\/td><td>2028\u20112029<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Revenue Projection<\/strong>: Analysts forecast <strong>\u00a5300\u2011500\u202fmillion<\/strong> (\u2248\u202fUS$42\u201170\u202fmillion) peak annual sales if approved, given the premium pricing of long-acting topical anesthetics.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Weixikang&#8217;s clinical development timelines, regulatory review, and market potential for lidocaine-tetracaine cream. Actual results may differ due to clinical outcomes, competitive dynamics, and regulatory uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/603676_20251204_6XPP.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603676_20251204_6XPP.\"><\/object><a id=\"wp-block-file--media-5b407ae2-7b69-4069-a1ba-69d070d9d93d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/603676_20251204_6XPP.pdf\">603676_20251204_6XPP<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/603676_20251204_6XPP.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5b407ae2-7b69-4069-a1ba-69d070d9d93d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tibet Weixikang Pharmaceutical Co., Ltd. (SHA: 603676) announced that its lidocaine-tetracaine cream has received approval&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50176,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,31,4492,4491],"class_list":["post-50172","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-generic-drugs","tag-sha-603676","tag-weixikang-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Tibet Weixikang Pharmaceutical Co., Ltd. (SHA: 603676) announced that its lidocaine-tetracaine cream has received approval from the China National Medical Products Administration (NMPA) to conduct clinical trials for local anesthesia of intact skin prior to adult dermatological surgeries.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50172\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval\" \/>\n<meta property=\"og:description\" content=\"Tibet Weixikang Pharmaceutical Co., Ltd. (SHA: 603676) announced that its lidocaine-tetracaine cream has received approval from the China National Medical Products Administration (NMPA) to conduct clinical trials for local anesthesia of intact skin prior to adult dermatological surgeries.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50172\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T13:23:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-08T13:23:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0806.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50172#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50172\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval\",\"datePublished\":\"2025-12-08T13:23:10+00:00\",\"dateModified\":\"2025-12-08T13:23:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50172\"},\"wordCount\":363,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50172#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0806.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Generic drugs\",\"SHA: 603676\",\"Weixikang Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50172#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50172\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50172\",\"name\":\"Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50172#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50172#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0806.webp\",\"datePublished\":\"2025-12-08T13:23:10+00:00\",\"dateModified\":\"2025-12-08T13:23:11+00:00\",\"description\":\"Tibet Weixikang Pharmaceutical Co., Ltd. (SHA: 603676) announced that its lidocaine-tetracaine cream has received approval from the China National Medical Products Administration (NMPA) to conduct clinical trials for local anesthesia of intact skin prior to adult dermatological surgeries.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50172#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50172\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50172#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0806.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0806.webp\",\"width\":1080,\"height\":608,\"caption\":\"Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50172#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval - Insight, China&#039;s Pharmaceutical Industry","description":"Tibet Weixikang Pharmaceutical Co., Ltd. (SHA: 603676) announced that its lidocaine-tetracaine cream has received approval from the China National Medical Products Administration (NMPA) to conduct clinical trials for local anesthesia of intact skin prior to adult dermatological surgeries.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50172","og_locale":"en_US","og_type":"article","og_title":"Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval","og_description":"Tibet Weixikang Pharmaceutical Co., Ltd. (SHA: 603676) announced that its lidocaine-tetracaine cream has received approval from the China National Medical Products Administration (NMPA) to conduct clinical trials for local anesthesia of intact skin prior to adult dermatological surgeries.","og_url":"https:\/\/flcube.com\/?p=50172","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-08T13:23:10+00:00","article_modified_time":"2025-12-08T13:23:11+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0806.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50172#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50172"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval","datePublished":"2025-12-08T13:23:10+00:00","dateModified":"2025-12-08T13:23:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50172"},"wordCount":363,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50172#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0806.webp","keywords":["Clinical trial approval \/ initiation","Generic drugs","SHA: 603676","Weixikang Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50172#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50172","url":"https:\/\/flcube.com\/?p=50172","name":"Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50172#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50172#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0806.webp","datePublished":"2025-12-08T13:23:10+00:00","dateModified":"2025-12-08T13:23:11+00:00","description":"Tibet Weixikang Pharmaceutical Co., Ltd. (SHA: 603676) announced that its lidocaine-tetracaine cream has received approval from the China National Medical Products Administration (NMPA) to conduct clinical trials for local anesthesia of intact skin prior to adult dermatological surgeries.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50172#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50172"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50172#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0806.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0806.webp","width":1080,"height":608,"caption":"Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50172#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0806.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50172"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50172\/revisions"}],"predecessor-version":[{"id":50177,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50172\/revisions\/50177"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50176"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}